©2024 Stanford Medicine
Study of Dextromethorphan in OCD and Related Disorders
Recruiting
I'm InterestedTrial ID: NCT04899687
Purpose
The purpose of the study is to assess the tolerability and efficacy of dextromethorphan in
combination with fluoxetine for symptom relief in OCD and related disorders.
Official Title
Fluoxetine/Dextromethorphan in Obsessive-Compulsive and Related Disorders: an Open-Label Crossover Pilot Study
Stanford Investigator(s)
Peter Johannes van Roessel
Clinical Associate Professor, Psychiatry and Behavioral Sciences
Carolyn Rodriguez
Professor of Psychiatry and Behavioral Sciences (Public Mental Health and Population Sciences)
Eligibility
Inclusion Criteria:
- Diagnosis of obsessive-compulsive disorder (OCD), body dysmorphic disorder (BDD),
illness anxiety disorder (IAD) or somatic symptom disorder (SSD)
- Living within California
- Capacity to provide informed consent
Exclusion Criteria:
- Current bipolar disorder or psychotic disorder
- Active moderate or severe substance use disorder, lifetime severe substance use
disorder
- Pregnant or nursing women
- Use of prescribed psychotropic medications other than fluoxetine for 2 weeks prior to
study start
- Having commenced OCD-targeted exposure and response-prevention (ExRP) psychotherapy
within 2 months of study start
Intervention(s):
drug: Fluoxetine
drug: Dextromethorphan
Recruiting
I'm InterestedContact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Pavithra Makunda, MS
650-723-4095